Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropenia-Reference-Cited by-同舟云学术

Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropenia

Published:2013-06-29 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Paul Mical¹,Dickstein Yaakov²,Schlesinger Agata³,Grozinsky-Glasberg Simona⁴,Soares-Weiser Karla⁵,Leibovici Leonard³

Affiliation:

1. Rambam Health Care Campus; Division of Infectious Diseases; Ha-aliya 8 St Haifa Israel 33705

2. Rambam Health Care Center; Medicine A and Unit of Infectious Diseases; Haifa Israel

3. Beilinson Hospital, Rabin Medical Center; Department of Medicine E; 39 Jabotinski Street Petah Tikva Israel 49100

4. Dept of Medicine, Hadassah-Hebrew University Medical Center; Neuroendocrine Tumors Unit, Endocrinology & Metabolism Service; POB 12000 Jerusalem Israel 91120

5. Cochrane; Cochrane Editorial Unit; St Albans House, 57 - 59 Haymarket London UK SW1Y 4QX

Publisher

Wiley

Subject

Pharmacology (medical)

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/14651858.CD003038.pub2/fullpdf

Reference152 articles.

1. Cost-effectiveness of cefepime + netilmicin or ceftazidime + amikacin or meropenem monotherapy in febrile neutropenic children with malignancy in Turkey;Agaoglu;Journal of Chemotherapy,2001

2. Ahmed N Borollosy N Beshlawy A Mahallawy H Haddad A Outpatient single dose ceftriaxone and amikacin vs. imipenem/cilastatin monotherapy in the empiric treatment of pediatric patients with high risk fever and neutropenia: a randomized, prospective clinical trial Proceedings of Meeting of the American Society of Hematology; Abstract No. 887 2003

3. Ahmed N Borollosy N Beshlawy A Mahallawy H Haddad A Outpatient single dose ceftriaxone and amikacin vs. imipenem/cilastatin monotherapy in the empiric treatment of pediatric patients with high risk fever aneutropenia: a randomized, prospective clinical trial Proceedings of ASCO Meeting; Abstract No. 8520 2004

4. Early hospital discharge versus continued hospitalization in febrile pediatric cancer patients with prolonged neutropenia: a randomized, prospective study;Ahmed;Pediatric Blood Cancer,2007

5. Comparison of meropenem with amikacin plus ceftazidime in the empirical treatment of febrile neutropenia: a prospective randomised multicentre trial in patients without previous prophylactic antibiotics. Meropenem Study Group of Turkey;Akova;International Journal of Antimicrobial Agents,1999

Cited by 76 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Global burden of anticancer drug-induced acute kidney injury and tubulointerstitial nephritis from 1967 to 2023;Scientific Reports;2024-07-12

2. Systematic Review of Beta-Lactam vs. Beta-Lactam plus Aminoglycoside Combination Therapy in Neutropenic Cancer Patients;Cancers;2024-05-19

3. ICU-acquired infections in immunocompromised patients;Intensive Care Medicine;2024-01-10

4. Pattern of bacterial infections in neutropenic febrile patients (experience of the Specialized BMT center - Medical city complex - Baghdad, Iraq);Iraqi Journal of Hematology;2024-01

5. Progress in the Diagnosis and Treatment of Pediatric Septic Shock;Advances in Clinical Medicine;2024